和铂医药公布 CTLA-4 联合 PD1 治疗结直肠癌最新临床数据

新浪财经10-23

（来源：求实药社）10 月 23 日，和铂医药公布了新一代全人源仅重链抗 CTLA-4 抗体普鲁苏拜单抗（HBM4003）联合替雷利珠单抗治疗微卫星稳定型（MSS）转移性结直肠癌（mCRC）的 II 期临床积极数据。在这一难治人群中，联合疗法展现出令人鼓舞的抗肿瘤活性及可控的安全性。这项多中心、开放标签的 II 期研究（NCT05167071）共纳入24 例既往接受过多线治疗的非肝转移性 MSS ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2577544965?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-23 12:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2577544965","market":"hk","top_or_hot":-1,"title":"和铂医药公布 CTLA-4 联合 PD1 治疗结直肠癌最新临床数据","media":"新浪财经","content":"<div>\n<p>（来源：求实药社）10 月 23 日，和铂医药公布了新一代全人源仅重链抗 CTLA-4 抗体普鲁苏拜单抗（HBM4003）联合替雷利珠单抗治疗微卫星稳定型（MSS）转移性结直肠癌（mCRC）的 II 期临床积极数据。在这一难治人群中，联合疗法展现出令人鼓舞的抗肿瘤活性及可控的安全性。这项多中心、开放标签的 II 期研究（NCT05167071）共纳入24 例既往接受过多线治疗的非肝转移性 MSS ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102312362294d8f652&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和铂医药公布 CTLA-4 联合 PD1 治疗结直肠癌最新临床数据</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和铂医药公布 CTLA-4 联合 PD1 治疗结直肠癌最新临床数据\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-23 12:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102312362294d8f652&s=b><strong>新浪财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>（来源：求实药社）10 月 23 日，和铂医药公布了新一代全人源仅重链抗 CTLA-4 抗体普鲁苏拜单抗（HBM4003）联合替雷利珠单抗治疗微卫星稳定型（MSS）转移性结直肠癌（mCRC）的 II 期临床积极数据。在这一难治人群中，联合疗法展现出令人鼓舞的抗肿瘤活性及可控的安全性。这项多中心、开放标签的 II 期研究（NCT05167071）共纳入24 例既往接受过多线治疗的非肝转移性 MSS ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102312362294d8f652&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102312362294d8f652&s=b","article_id":"2577544965","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102312362294d8f652&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2577544965","pubTimestamp":1761192000,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"10 月 23 日，和铂医药公布了新一代全人源仅重链抗 CTLA-4 抗体普鲁苏拜单抗联合替雷利珠单抗治疗微卫星稳定型转移性结直肠癌的 II 期临床积极数据。在这一难治人群中，联合疗法展现出令人鼓舞的抗肿瘤活性及可控的安全性。这项多中心、开放标签的 II 期研究共纳入24 例既往接受过多线治疗的非肝转移性 MSS mCRC 患者。主要疗效终点为基于 RECIST 1.1 标准的客观缓解率。结果显示，疗效方面，在 23 例可评估患者中，联合治疗展现出良好的抗肿瘤活性。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","BK1574":"生物医药B类股","02142":"和铂医药-B","BK1161":"生物科技"},"translate_title":"Hebo Pharmaceuticals announces the latest clinical data of CTLA-4 combined with PD1 in the treatment of colorectal cancer","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1.5},"content_text":"（来源：求实药社）10 月 23 日，和铂医药公布了新一代全人源仅重链抗 CTLA-4 抗体普鲁苏拜单抗（HBM4003）联合替雷利珠单抗治疗微卫星稳定型（MSS）转移性结直肠癌（mCRC）的 II 期临床积极数据。在这一难治人群中，联合疗法展现出令人鼓舞的抗肿瘤活性及可控的安全性。这项多中心、开放标签的 II 期研究（NCT05167071）共纳入24 例既往接受过多线治疗的非肝转移性 MSS mCRC 患者。患者每 21 天接受 HBM4003（0.3 mg/kg）联合替雷利珠单抗（200 mg）治疗。主要疗效终点为基于 RECIST 1.1 标准的客观缓解率（ORR）。所有患者（N=24）既往均接受过≥二线治疗；16/24（66.7%）的患者存在肺转移。结果显示，疗效方面，在 23 例可评估患者中，联合治疗展现出良好的抗肿瘤活性。客观缓解率（ORR）：34.8%（8 例部分缓解）疾病控制率（DCR）：60.9%（8 例部分缓解+6 例疾病稳定）中位无进展生存期（mPFS）：4.2 个月安全性方面，该治疗方案耐受性良好，未观察到 4 级或致死的治疗期间出现的不良事件（TEAEs）。治疗相关不良事件（TRAEs）发生率为 87.5%（21/24），最常见（发生率≥20%）为肝功能异常、血液学异常和发热（多为 1-2 级)。治疗相关严重不良事件（SAEs）发生率为 37.5%（9/24）。鲁苏拜单抗是和铂医药自 HCAb Harbour Mice® 平台开发的新一代全人源仅重链抗 CTLA-4 抗体，是全球首个进入临床阶段的全人源仅重链抗体。文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担, 关于对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577544965","isCrawlerRequest":true}